U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	Complete if Known		
	Application Number	10/741,534	
INFORMATION DISCLOSURE	Filing Date	12/19/03	
STATEMENT BY APPLICANT	First Named Inventor	Alain Baron	
	Art Unit	1647	
(Use as many sheets as necessary)	Examiner Name	STOICA, Elly Gerald	
eet 1 of 3	Attorney Docket Number	0218US-UTL	

			<u>u. S. P</u> ate	ENT DOCUM	ENTS		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code <sup>2 (If known)</sup>	Publication Da MM-DD-YYY	ite Na	ame of Patentee or ant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevar Figures Appear	e nt
		US-5,254,372	10-19-1993	NICHO	LS		
		US-		***************************************			_
	**************	US-					
	, 1° 1 *** 1 *** 1 1 1 1 1 1 1 1 1 1 1 1	US-				**************************************	
		US-					
		US-					
		US-					
		US-					
		us-					
		US-				194401111111111111111111111111111111111	
		US-			•		
		us-					
		US-					
***************************************		US-					
	***************************************	US-	· · · · · · · · · · · · · · · · · · ·				
		US-					
		US-					
		US-					
			FOREIGN PA	TENT DOCL	IMENTO		_
	l			TENT DOCK	MICHIS		Т
Examiner Cite No.1	Cite	Foreign Patent Doc	ument	Publication Date Name of Patentee or MM-DD-YYYY Applicant of Cited Docum			
	110.	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )		VIIVI-DD-1111	Applicant of Cited Docum	or Relevant Figures Appear	
	<u></u>						ſ
							ï
**************	<b></b>				•••••••••••••••••••••••••••••••••••••••		۳
***************************************			•••••••••••••••••••••••••••••••••••••••	••••••••••••		·······	╌┣

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known Application Number 10/741,534 INFORMATION DISCLOSURE Filing Date 12/19/03 STATEMENT BY APPLICANT First Named Inventor Alain Baron Art Unit 1647 (Use as many sheets as necessary) Examiner Name STOICA, Elly Gerald 0218US-UTL Sheet 3 Attorney Docket Number

η	·	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		International Search Report from PCT/US03/040504 (WO 2004/056313)	
***************************************	1	BARTLETT, et al., "Inhibition of Chymotrypsin by Phosphonate and	***********
		Phosphonamidate Peptide Analogs", Bioorganic Chemistry, 14, 356-377 (1986)	
***************************************	1	DEACON, et al., "Dipeptidyl Peptidase IV Resistant Analogues of Glucagon-	**********
		Like Peptide-1:In Vitro and In Vivo Studies", Diabetologia 40, Supp 1:A127	
***************************************		Abstract No. 492 (1997)	
		HARETER, et al, "Role of Histidine 7 in GLP-1 (7-36)Amide Action:	
		Diabetes 46, Supp. 1: 191A, Abstract No. 0734 (1997)	
••••••	<b>†</b>	IRWIN, et al., "The Xenopus Proglucagon Gene Encodes Novel GLP-1-Like	
		Peptides with Insulinotropic Properties", Proc. Natl. Acad. Sci.USA,	
		94: 7915-7920 (1997)	**********
***************************************	<b></b>	NIKOLAIDIS, et al., "GLP-1 Improves Myocardian Performance in Conscious	***********
		Dogs With Pacing Induced Heart Failure", Journal of the American College of	
***************************************		Cardiology, 37(2), Supp. 1, Abstract E886-5, page 218A (2001)	
***************************************	<b></b>	ORSKOV, et al, "Proglucagon Products in Plasma of Noninsulin-dependent Diab	etic:
		and Nondiabetic Controls in the Fasting State and After Oral Glucose and In	trav
		Arginine", J. Clin. Invest., 87:415-423 (1991)	

Examiner Signature Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT \$END FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
				Application Number	10/741,534		
INFORMATION DISCLOSURE			SURE	Filing Date	12/19/03		
STAT	STATEMENT BY APPLICANT		First Named Inventor	Alain Baron			
				Art Unit	1647		
(Use as many sheets as necessary)		Examiner Name	STOICA, Elly Gerald				
Sheet	3	of	3	Attorney Docket Number	0218US-UTL		

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Remington's Pharmaceutical Sciences, 18th Ed., Wiley Publishing (1990)
:		SIEGEL, et al., "Biological Activity of GLP-1 Analogues with N-Terminal Modifications", <i>Diabetes</i> (46), Supp. 1: 187A, Abstract No. 0719 (1997)
		WATERMAN, "General Methods of Sequence Comparison", Bulletin of Mathematical Biology, 46(4):473-500 (1984)
	***************************************	
***************************************		
	**************	
Examiner Signature		Date

	1	
Examiner	1 _	1
⊏xammer	Date	
O: 1		1
Signature	Considered	1
Try natare	Considered	1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.